Format

Send to

Choose Destination
Nat Med. 2018 May;24(5):647-657. doi: 10.1038/s41591-018-0004-z. Epub 2018 Apr 9.

Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.

Author information

1
Gladstone Institute of Neurological Disease, San Francisco, CA, USA.
2
Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
3
Developmental and Stem Cell Biology Program, University of California, San Francisco, San Francisco, CA, USA.
4
Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
5
Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.
6
Gladstone Institute of Neurological Disease, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.
7
Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.
8
Developmental and Stem Cell Biology Program, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.
9
Department of Pathology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.

Abstract

Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems. Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration. ApoE4 increased Aβ production in human, but not in mouse, neurons. Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4. Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4. Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center